A Multicenter Physician Survey Evaluating the Use of Ki-67 in Breast Cancer Management in Canada
Despite the widespread availability of Ki-67 testing, few physicians in Canada currently use it to assess endocrine response, predominantly due to logistical and resource constraints. There is a high level of interest in participating in future trials using this strategy, which should focus on disease related outcomes, feasibility, and the financial impact on the public healthcare system.
Authors
- Moira Rushton (ORCID: https://orcid.org/0000-0002-5178-2538)
- Jennifer Leigh (ORCID: https://orcid.org/0000-0002-7431-3574)
- Sharon F. McGee (ORCID: https://orcid.org/0000-0002-0323-6372)
- Lisa Vandermeer (ORCID: https://orcid.org/0000-0001-5921-1441)
- Phillip Williams (ORCID: https://orcid.org/0000-0003-4884-2453)
Institutions
- Ottawa Hospital (CA)
- Ottawa Hospital Research Institute (CA)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3390/biomedicines12112471
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00